Updating the management of rectal cancer

Journal of Gastrointestinal and Liver Diseases

Volumn 17, Issue 1, 2008, Pages 69-74

  Nagy, Viorica Magdalena ^a,b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

Author keywords

Radiochemotherapy; Rectal cancer; Surgery

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; IRIDIUM 192; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; RALTITREXED;

ABDOMINAL CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COLON RESECTION; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG TARGETING; ENDOSCOPIC ECHOGRAPHY; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; META ANALYSIS; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS CANCER; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; RADIATION DOSE; RECTUM CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

COMBINED MODALITY THERAPY; HUMANS; NEOPLASM STAGING; RECTAL NEOPLASMS;

EID: 42449163899     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging - a meta-analysis. Radiology 2004; 232: 773-783.
2. Sailer M, Leppert R, Kraemer M, Fuchs KH, Thiede A. The value of endorectal ultrasound in the assessment of adenomas, T1- and T2 - carcinomas. Int J Colorectal Dis 1997; 12: 214-219.
3. Kantorova I, Lipska L, Belohlavek O, Visokai V, Trubac M, Schneiderova M. Routine (18)F-FDG PET preoperative staging of colorectal cancer; comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003; 44: 1784-1788.
4. Chessin DB, Kiran RP, Akhurst T, Guillem JG. The emerging role of 18F fluorodeoxyglucose positron emission tomography in the management of primary and recurrent rectal cancer. J Am Coll Surg 2005; 1: 948-956.
5. Albrecht T, Hohmann J, Oldenburg A, Skrok J, Wolf KJ. Detection and characterization of liver metastases. Eur Radiol 2004; 14 (Suppl 8): P25-P33.
6. Van Etten B, Van Der Sijp J, Kruyt R, Oudkerk M, van der Holt B, Wiggers T.. Ferumoxide- enhanced magnetic resonance imaging techniques in pre-operative assessment for colorectal liver metastases. Eur J Surg Oncol 2002; 28: 645-651.
7. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1: 1479-1482.
8. Kapiteijn E, Putter H, van de Velde CJ; Cooperative investigators of the Dutch ColoRectal Cancer Group. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002; 89: 1142-1149.
9. Tepper JE, O'Connell MJ, Niedzwiecki D, et al. Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001; 19: 157-163.
10. Guillou PJ, Quirke P, Thorpe H, et al. Short-term endpoints of conventional versus laparascopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 2005; 365: 1718-1726.
11. Madbouly KM, Remzi FH, Erkel BA, et al. Recurrence after transanal excision of T1 rectal cancer: should we be concerned? Dis Colon Rectum 2005; 48: 711-719.
12. Roels S, Duthoy W, Haustermans K, et al. Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys 2006; 65: 1129-1142.
13. Gerard JP, Chapet O, Nemoz C, et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the Lyon R96-02 randomized trial. J Clin Oncol 2004; 22: 2404-2409.
14. Wagman RT, Minsky BD. Conservative management of rectal cancer with local excision and adjuvant therapy. Oncology (Williston Park) 2001; 15: 513-519.
15. Benson R, Wong CS, Cummings BJ, et al. Local excision and postoperative radiotherapy for distal rectal cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1309-1316.
16. Lezoche E, Guerrieri M, Paganini AM, Feliciotti F. Long-term results of patients with pT2 rectal cancer treated with radiotherapy and transanal endoscopic microsurgical excision. World J Surg 2002; 26: 1170-1174.
17. Bonnen M, Cranc C, Vauthey JN, et al. Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. Int J Radiat Oncol Biol Phys 2004; 60: 1098-1105.
18. Minsky BD, Conti JA, Huang Y, Knopf K. Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol 1995; 13: 1409-1416.
19. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444-1450.
20. O'Connell MJ, Martenson JA, Wicand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994; 331: 502-507.
21. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.
22. Valentini V. Radiotherapy combined with other treatments in rectal cancer. Tumori 1998; 84: 238-246.
23. Glimelius B, Gronberg H, Jarhult J, Wallgren A, Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003; 42: 476-492.
24. Bosset JF, Collette L, Calais G, et al; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123.
25. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625.
26. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999; 17: 2396.
27. Stein DE, Mahmoud NN, Anne PR, et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 2003; 46:448-453.
28. Valentini V, Coco C, Cellini N, et al. Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys 1999; 45: 1175-1184.
29. Kim JC, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 3, 403-408.
30. Cividalli A, Ceciarelli F, Lovdi E, et al. Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule. Int J Radiat Oncol Biol Phys 2002; 52: 1092-1098.
31. Carraro S, Roca EI, Cartelli C, et al. Radiochemotherapy with daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study. Int J Radiat Oncol Biol Phys 2002; 54, 397-402.
32. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104.
33. Wang LW, Yang SH, Lin JK, et al. Pre-operative chemoradiotherapy with oral tegafur-uracil and leucovorin for rectal cancer. J Surg Oncol 2005; 89: 256-263.
34. Gambacorta MA, Valentini V, Coco C, et al. Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III respectable rectal cancer. Phase I and II studies. Int J Radiat Oncol Biol Phys 2004; 60: 139-148.
35. Saltz LB, Lenz HJ, Hochster H. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol 2005; 23 (suppl, abstr 3508): 248s.
36. Venook A, Niedzwiecki D, Hollis D. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients with untreated metastatic adenocarcinoma of the colon and rectum: CALGB 80203 preliminary results. J Clin Oncol 2006; 24 (suppl 188, abstr 3509): 148s.
37. Giantonio BJ, Catalano PJ, Meropol NJ. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study 3200. J Clin Oncol 2005; 23 (suppl 168, abstr 2): 1s.
38. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sakar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712.